The HIVRAD Program described in this application consists of scientists from several disciplines located in a wide geographical area, stretching from the West Coast of the US to the West Coast of Africa (Cameroon). This Core is designed to facilitate communication among the scientists, the institutions, and among the Pis of each Project, the Cores, and the co-investigators and consultants. In addition, it will facilitate communication between Pis of this and other HIVRADs as well as the DAIDS staff and the Scientific Advisory Board (SAB) of this HIVRAD. Therefore, Core A provides services to all Projects and Scientific Cores. Core A is structured around three Specific Aims:
Aim 1. To promote open discussion and communication among members, facilitate sharing of scientific data and resources, and enable periodic strategic planning. To accomplish this, the administrative staff will organize and coordinate a) monthly teleconferences of the Executive Committee, b) monthly Work-in-Progress videoteleconferences in which, during each session, the leader or a member of a different Project or Core will present an update of on-going work, c) bi-annual meetings of all HIVRAD participants, and d) annual meetings of the SAB to be held in conjunction with the DAIDS site visit.
Aim 2. To maintain the password-protected SharePoint web portal we have established (http://sp.nvumc.org/nvuhiv/default.aspx) which includes blogs for each Project (to promote free and open communication among members), data libraries for each Project and Core (to afford easy browsing and searching of all data), Powerpoint presentations, progress reports, manuscripts (in preparation and in press), and inventories of reagents (monoclonal Abs, protein immunogens, DNA vaccines, viruses, etc.). This portal will be password-protected and accessible via internet from any computer in the world.
And Aim 3. To regularly monitor the performance of all scientific projects and to track the expenditures for each Project and Core. This Core will evaluate and report on progress to the SAB and the DAIDS staff, as well as monitor the implementation of changes recommended by the SAB and DAIDS.
Efficient management is essential for the efficient functioning of a multi-institutional program. Through its activities, this Core will facilitate the achievement of the goals of each of the Projects and Cores, and of the Program as a whole.
|Mayr, Luzia M; Decoville, Thomas; Schmidt, Sylvie et al. (2017) Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. Sci Rep 7:12655|
|Powell, Rebecca L R; Totrov, Maxim; Itri, Vincenza et al. (2017) Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. J Virol 91:|
|Balasubramanian, Preetha; Kumar, Rajnish; Williams, Constance et al. (2017) Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Vaccine 35:1464-1473|
|Musich, Thomas; Li, Liuzhe; Liu, Lily et al. (2017) Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. J Virol 91:|
|Horwitz, Joshua A; Bar-On, Yotam; Lu, Ching-Lan et al. (2017) Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell 170:637-648.e10|
|Jiang, Xunqing; Totrov, Max; Li, Wei et al. (2016) Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. J Virol 90:11007-11019|
|Zolla-Pazner, Susan; Powell, Rebecca; Yahyaei, Sara et al. (2016) Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. J Virol 90:10993-11006|
|Zolla-Pazner, Susan (2016) Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. AIDS 30:2551-2553|
|Hessell, Ann J; McBurney, Sean; Pandey, Shilpi et al. (2016) Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. Vaccine 34:2713-21|
|McFarren, Alicia; Lopez, Lillie; Williams, Dionna W et al. (2016) A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier. AIDS 30:563-72|
Showing the most recent 10 out of 42 publications